Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

New Technology Generates Cancer Killing Antibody Drug Conjugates

By BiotechDaily International staff writers
Posted on 11 Mar 2014
Image: In order to overcome the known limitations inherent to chemical conjugation of small molecule toxic drugs to antibodies, NBE-Therapeutics has developed a patent-pending technology for the specific enzymatic conjugation of drugs to antibodies (Photo courtesy of NBE-Therapeutics).
Image: In order to overcome the known limitations inherent to chemical conjugation of small molecule toxic drugs to antibodies, NBE-Therapeutics has developed a patent-pending technology for the specific enzymatic conjugation of drugs to antibodies (Photo courtesy of NBE-Therapeutics).
A novel technology for generation of specific toxin-bearing antibodies for treatment of cancer has been validated in a recent series of proof-of-concept studies.

NBE-Therapeutics (Basel, Switzerland) presented evidence of the successful validation of its enzymatic SMAC-Technology for the generation of potent next-generation antibody drug conjugates (ADCs) at the international World ADC summit held in Frankfurt (Germany).

NBE-Therapeutics' patent-pending SMAC (sortase-mediated antibody conjugation)-Technology utilizes highly selective sortase enzymes for site-specific and efficient conjugation of toxic payloads to therapeutic antibodies. Sortases are a group of prokaryotic enzymes that modify surface proteins by recognizing and cleaving a carboxyl-terminal sorting signal. For most substrates of sortase enzymes, the recognition signal consists of the motif LPXTG (leucine-proline-any amino acid-threonine-glycine), then a highly hydrophobic transmembrane sequence, then a cluster of basic residues such as arginine. Cleavage occurs between the threonine and glycine. Sortases occur in almost all gram-positive bacteria and the occasional gram-negative.

ADCs represent a new type of targeted therapy, in which highly potent cellular toxins (toxic payloads) are conjugated to cancer-specific antibodies allowing the targeted destruction of cancer cells without affecting healthy cells or tissue.

In proof-of-concept studies, it was demonstrated that SMAC-generated ADCs displayed the same potencies in cancer cell killing experiments as commercially available benchmark ADCs composed of identical antibody and toxin, even when significantly smaller amount of toxic payload was conjugated.

The company is now planning to leverage its SMAC-Technology for the development of a preclinical and clinical pipeline of next-generation ADC products, aimed at providing improved targeted therapies for difficult to treat cancers.

Related Links:

NBE-Therapeutics 



Channels

Lab Technologies

view channel
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).

High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification

A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.